Analysts forecast that EXACT Sciences Co. (NASDAQ:EXAS) will report $109.20 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for EXACT Sciences’ earnings. The highest sales estimate is $110.70 million and the lowest is $108.10 million. EXACT Sciences reported sales of $72.57 million during the same quarter last year, which indicates a positive year over year growth rate of 50.5%. The company is expected to issue its next quarterly earnings results on Monday, October 29th.

According to Zacks, analysts expect that EXACT Sciences will report full-year sales of $427.60 million for the current fiscal year, with estimates ranging from $425.00 million to $429.00 million. For the next year, analysts expect that the business will report sales of $661.57 million per share, with estimates ranging from $601.70 million to $700.05 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow EXACT Sciences.

EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Wednesday, August 1st. The medical research company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. EXACT Sciences had a negative return on equity of 20.10% and a negative net margin of 35.24%. The firm had revenue of $102.89 million for the quarter, compared to analysts’ expectations of $104.40 million. During the same period in the prior year, the business posted ($0.27) earnings per share. The business’s revenue was up 78.5% compared to the same quarter last year.

A number of analysts have weighed in on the company. BidaskClub upgraded EXACT Sciences from a “hold” rating to a “buy” rating in a research report on Friday, August 31st. Goldman Sachs Group upped their price target on EXACT Sciences to $75.00 and gave the company a “neutral” rating in a research report on Thursday, August 30th. Jefferies Financial Group reiterated a “buy” rating and issued a $74.00 price target on shares of EXACT Sciences in a research report on Thursday, August 23rd. Cowen upped their price target on EXACT Sciences from $65.00 to $85.00 and gave the company an “outperform” rating in a research report on Monday, June 18th. Finally, Craig Hallum upped their price target on EXACT Sciences from $54.00 to $74.00 and gave the company a “buy” rating in a research report on Thursday, August 23rd. Three equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. EXACT Sciences currently has an average rating of “Buy” and a consensus target price of $75.18.

In other EXACT Sciences news, SVP D Scott Coward sold 2,135 shares of the business’s stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $59.10, for a total value of $126,178.50. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Michael S. Wyzga sold 2,468 shares of the business’s stock in a transaction on Tuesday, August 28th. The stock was sold at an average price of $74.85, for a total value of $184,729.80. Following the completion of the transaction, the director now directly owns 9,112 shares in the company, valued at approximately $682,033.20. The disclosure for this sale can be found here. In the last three months, insiders sold 17,014 shares of company stock worth $1,031,717. Insiders own 3.20% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. Asymmetry Capital Management L.P. boosted its stake in EXACT Sciences by 229.2% in the second quarter. Asymmetry Capital Management L.P. now owns 84,937 shares of the medical research company’s stock worth $5,078,000 after purchasing an additional 59,134 shares in the last quarter. Sit Investment Associates Inc. lifted its stake in shares of EXACT Sciences by 24.3% during the second quarter. Sit Investment Associates Inc. now owns 33,300 shares of the medical research company’s stock valued at $1,991,000 after acquiring an additional 6,500 shares during the period. Hartford Investment Management Co. acquired a new position in shares of EXACT Sciences during the second quarter valued at $202,000. Swiss National Bank lifted its stake in shares of EXACT Sciences by 1.4% during the second quarter. Swiss National Bank now owns 210,619 shares of the medical research company’s stock valued at $12,593,000 after acquiring an additional 3,000 shares during the period. Finally, Gofen & Glossberg LLC IL acquired a new position in shares of EXACT Sciences during the second quarter valued at $469,000. 86.40% of the stock is currently owned by institutional investors.

Shares of NASDAQ:EXAS opened at $77.60 on Wednesday. EXACT Sciences has a fifty-two week low of $37.36 and a fifty-two week high of $77.75. The firm has a market capitalization of $9.19 billion, a price-to-earnings ratio of -78.38 and a beta of 0.95. The company has a current ratio of 15.79, a quick ratio of 15.37 and a debt-to-equity ratio of 0.87.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Further Reading: Outstanding Shares and The Effect on Share Price

Get a free copy of the Zacks research report on EXACT Sciences (EXAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.